OsteoporosisWRAP

Focus on the Evolution of Clinical Efficacy of Bisphosphonates for Postmenopausal Osteoporosis

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This course is designed for primary care physicians, family medicine specialists, bone metabolism experts, preventive medicine specialists, gynecologists, nurse practitioners, orthopedic surgeons, consulting pharmacists, internal medicine specialists, endocrinologists, women's health physicians, geriatric nurse practitioners, and rheumatologists.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAP and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

This activity is supported by an Independent Educational Grant from Roche Laboratories Inc.

Designation of Credit:

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS). The UMMS is accredited by ACCME to provide continuing medical education for physicians.

The UMMS designates this continuing medical education activity for up to 1 credit hour in Category 1 toward the Physicians Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Statement of Disclosure:

In accordance with the Standards of the Accreditation Council for Continuing Medical Education (ACCME) and the guidelines of the Association of American Medical Colleges (AAMC), it is the policy of the University of Massachusetts Medical School to disclose whatever interest or affiliation a speaker might have with any commercial organization whose products or services are related to the subject matter being presented.

Faculty Disclosures:

Grants/research support: Procter and Gamble Pharmaceuticals, IRIS (Paris) and Genzyme Corporation. Speaker's Bureau: Alliance for Better Bone Health, Procter and Gamble, Sanofi-Aventis Pharmaceuticals, Novartis, Merck, Roche, GlaxoSmithKline.

Mone Zaidi, MD, PhD, FRCP
Professor of Medicine and Physiology,
Director, Mount Sinai Bone Program,
Mount Sinai School of Medicine,
New York, New York

Educational Objectives:

• Practitioners will learn to risk stratify patients at risk for osteoporosis and /or related complications, and identify optimal therapeutic approaches.
• Practitioners will learn to undertake a systematic evaluation of patients at risk for osteoporosis, including radiological examination and appropriate laboratory markers.
• Practitioners will learn evidence-based approaches to reducing progression of osteoporosis and risk of fracture complications.
• Practitioners will learn how to select safe and effective pharmacotherapy for prevention and treatment of postmenopausal osteoporosis.
• Practitioners will learn how landmark trials and analyses focusing on BMD, bisphosphonate therapy, predictive risk, and fracture reduction should guide clinical management of patients with osteoporosis.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright (c) 2007 All rights reserved